RDNT on Nasdaq
RadNet, Inc.
In its 2026 annual report the company says: “We are a leading national provider of diagnostic imaging services in the United States based on number of locations and annual imaging revenue. Our principal business segment is the provision of diagnostic imaging services. Our Imaging Centers segment provides physicians with capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients.”4 It is headquartered in Los Angeles, California.1 Its shares trade on Nasdaq under the symbol RDNT.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Natera, Fortrea Holdings Inc. or Exact Sciences, or pick any stock.
- TickerRDNT on Nasdaq1
- IndustryServices-Medical Laboratories1
- HeadquartersLos Angeles, California1
- Incorporated inDE2
- Business address1510 Cotner Ave, Los Angeles, Ca 900252
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are a leading national provider of diagnostic imaging services in the United States based on number of locations and annual imaging revenue. We have been in business since 1985. Our principal business segment is the provision of diagnostic imaging services. As of December 31, 2025, we operated, directly or indirectly through hospital and health system joint ventures, 418 imaging centers located in Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, Texas and New York.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
3.0%Operating margin5
-0.9%Net margin5
11.5%Revenue growth, 20255
-1.7%Return on equity5
0.98×Debt to equity5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Commercial Insurance1 brought in 55% of the revenue RadNet, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Commercial Insurance1 | $879.8M | $1.0B | $1.1B |
| Medicare1 | $356.5M | $410.1M | $477.0M |
| Capitation Arrangements | $153.4M | $136.6M | $125.5M |
| Other Payors | $87.7M | $104.9M | $118.6M |
| Health Care, Other | $32.6M | $46.7M | $65.0M |
| Medicaid1 | $42.3M | $44.7M | $51.7M |
| Workers' Compensation/Personal Injury1 | $46.4M | $43.7M | $44.7M |
| Health Care, Management Service | $17.9M | $24.7M | $27.5M |
Business segments
Imaging Centers brought in 96% of the revenue RadNet, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Imaging Centers | $1.6B | $1.8B | $2.0B |
| Digital Health | $49.6M | $65.7M | $92.7M |
Regions
United States brought in 98% of the revenue RadNet, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.6B | $1.8B | $2.0B |
| Outside the United States | $16.9M | $27.2M | $34.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs99¢$2.0B
- Income tax1¢$14.9M
Out of $2.0B in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$298.8M
Out of $298.8M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total service revenue | $2.0B | $1.8B | $1.6B |
| Cost of operations, excluding depreciation and amortization | $1.8B | $1.6B | $1.4B |
| Lease abandonment charges | $8.6M | $2.5M | $5.1M |
| Depreciation and amortization | $152.1M | $137.8M | $128.4M |
| Gain on contribution of imaging centers into joint venture | $0 | $0 | -$16.8M |
| Loss on sale and disposal of equipment | $9.7M | $2.3M | $2.2M |
| Severance costs | $3.1M | $1.9M | $3.8M |
| Total operating expenses | $2.0B | $1.7B | $1.5B |
| INCOME FROM OPERATIONS | $62.0M | $104.6M | $98.7M |
| Interest expense | $69.9M | $79.8M | $64.5M |
| Equity in earnings of joint ventures | -$14.9M | -$14.5M | -$6.4M |
| Non-cash change in fair value of interest rate swaps | $7.1M | $8.0M | $8.2M |
| Debt restructuring and extinguishment expenses | $0 | $11.3M | $0 |
| Other income | -$32.1M | -$24.9M | -$6.4M |
| Total other expenses | $30.1M | $59.8M | $59.9M |
| Income before income taxes | $31.9M | $44.9M | $38.8M |
| Provision for income taxes | -$14.9M | -$6.0M | -$8.5M |
| NET INCOME | $17.0M | $38.8M | $30.3M |
| Net income attributable to noncontrolling interest | $35.7M | $36.0M | $27.3M |
| NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | -$18.7M | $2.8M | $3.0M |
| BASIC NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) | -$0.25 | $0.04 | $0.05 |
| DILUTED NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS (in dollars per share) | -$0.25 | $0.04 | $0.05 |
| Basic (in shares) | 75.2M shares | 73.0M shares | 63.6M shares |
| Diluted (in shares) | 75.2M shares | 74.8M shares | 64.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $767.2M | $740.0M | ||
| Accounts receivable, net | $200.3M | $185.8M | ||
| Prepaid expenses and other current assets | $52.0M | $51.5M | ||
| Total current assets | $1.0B | $1.0B | ||
| Property and equipment, net | $807.7M | $694.8M | ||
| Operating lease right-of-use assets | $690.2M | $639.7M | ||
| Total property, equipment and right-of-use assets | $1.5B | $1.3B | ||
| Goodwill | $907.7M | $710.7M | $679.5M | |
| Other intangible assets | $148.5M | $81.4M | ||
| Deferred financing costs | $1.7M | $2.3M | ||
| Investment in joint ventures | $130.3M | $104.1M | $92.7M | |
| Deposits and other | $40.3M | $34.6M | ||
| Total assets | $3.8B | $3.3B | ||
| Accounts payable, accrued expenses and other | $422.0M | $351.5M | ||
| Deferred revenue | $7.3M | $3.3M | ||
| Current portion of operating lease liability | $61.9M | $56.6M | ||
| Current portion of notes payable | $25.4M | $24.7M | ||
| Total current liabilities | $586.8M | $479.7M | ||
| Long-term operating lease liability | $707.0M | $656.0M | ||
| Notes payable, net of current portion | $1.1B | $991.6M | ||
| Deferred tax liability, net | $21.9M | $22.2M | ||
| Other non-current liabilities | $22.5M | $3.8M | ||
| Total liabilities | $2.4B | $2.2B | ||
| Common stock - $.0001 par value, 200,000,000 shares authorized; 77,399,615 and 74,036,993 shares issued and outstanding at December 31, 2025 and 2024 respectively | $8.0K | $7.0K | ||
| Additional paid-in-capital | $1.2B | $988.1M | ||
| Accumulated other comprehensive income (loss) | $4.9M | -$9.1M | ||
| Accumulated deficit | -$95.4M | -$76.8M | ||
| Total RadNet, Inc.'s stockholders' equity | $1.1B | $902.3M | ||
| Noncontrolling interests | $266.0M | $231.1M | ||
| Total equity | $1.4B | $1.1B | $813.4M | $491.5M |
| Total liabilities and equity | $3.8B | $3.3B | ||
| Common stock - par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock - authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock - issued (in shares) | 77.4M shares | 77.4M shares | ||
| Common stock - outstanding (in shares) | 74.0M shares | 74.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $767.2M | $740.0M | ||
| Accounts receivable, net | $200.3M | $185.8M | ||
| Prepaid expenses and other current assets | $52.0M | $51.5M | ||
| Total current assets | $1.0B | $1.0B | ||
| Property and equipment, net | $807.7M | $694.8M | ||
| Operating lease right-of-use assets | $690.2M | $639.7M | ||
| Total property, equipment and right-of-use assets | $1.5B | $1.3B | ||
| Goodwill | $907.7M | $710.7M | $679.5M | |
| Other intangible assets | $148.5M | $81.4M | ||
| Deferred financing costs | $1.7M | $2.3M | ||
| Investment in joint ventures | $130.3M | $104.1M | $92.7M | |
| Deposits and other | $40.3M | $34.6M | ||
| Total assets | $3.8B | $3.3B | ||
| Accounts payable, accrued expenses and other | $422.0M | $351.5M | ||
| Deferred revenue | $7.3M | $3.3M | ||
| Current portion of operating lease liability | $61.9M | $56.6M | ||
| Current portion of notes payable | $25.4M | $24.7M | ||
| Total current liabilities | $586.8M | $479.7M | ||
| Long-term operating lease liability | $707.0M | $656.0M | ||
| Notes payable, net of current portion | $1.1B | $991.6M | ||
| Deferred tax liability, net | $21.9M | $22.2M | ||
| Other non-current liabilities | $22.5M | $3.8M | ||
| Total liabilities | $2.4B | $2.2B | ||
| Common stock - $.0001 par value, 200,000,000 shares authorized; 77,399,615 and 74,036,993 shares issued and outstanding at December 31, 2025 and 2024 respectively | $8.0K | $7.0K | ||
| Additional paid-in-capital | $1.2B | $988.1M | ||
| Accumulated other comprehensive income (loss) | $4.9M | -$9.1M | ||
| Accumulated deficit | -$95.4M | -$76.8M | ||
| Total RadNet, Inc.'s stockholders' equity | $1.1B | $902.3M | ||
| Noncontrolling interests | $266.0M | $231.1M | ||
| Total equity | $1.4B | $1.1B | $813.4M | $491.5M |
| Total liabilities and equity | $3.8B | $3.3B | ||
| Common stock - par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock - authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock - issued (in shares) | 77.4M shares | 77.4M shares | ||
| Common stock - outstanding (in shares) | 74.0M shares | 74.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | $17.0M | $38.8M | $30.3M |
| Depreciation and amortization | $152.1M | $137.8M | $128.4M |
| Non-cash lease expense | $59.9M | $60.6M | $61.1M |
| Equity in earnings of joint ventures, net of dividend | -$5.8M | -$9.9M | $9.2M |
| Amortization of deferred financing costs and loan discount | $3.0M | $3.1M | $3.0M |
| Loss on sale and disposal of equipment | $9.7M | $2.3M | $2.2M |
| Loss on extinguishment of debt | $0 | $3.9M | $0 |
| Gain on contribution of imaging centers into joint venture | $0 | $0 | -$16.8M |
| Lease abandonment charges | $8.6M | $2.5M | $5.1M |
| Amortization of cash flow hedge | $2.3M | $9.4M | $3.6M |
| Non-cash change in fair value of interest rate swaps | $7.1M | $8.0M | $8.2M |
| Stock-based compensation | $54.6M | $29.8M | $26.8M |
| Loss on impairment | $0 | $1.3M | $3.9M |
| Change in fair value of contingent consideration | $111.0K | $2.0M | -$3.9M |
| Accounts receivable | -$9.6M | -$21.8M | $2.6M |
| Other current assets | $2.3M | -$32.8M | -$8.4M |
| Other assets | -$5.7M | $10.7M | -$1.5M |
| Deferred taxes | $10.8M | $6.5M | $6.1M |
| Operating lease liability | -$62.8M | -$54.9M | -$54.8M |
| Deferred revenue | $2.8M | -$1.4M | $626.0K |
| Accounts payable, accrued expenses and other | $52.4M | $37.1M | $15.1M |
| Net cash provided by operating activities | $298.8M | $233.0M | $220.9M |
| Purchase of imaging facilities and other acquisitions, net of cash acquired | -$133.4M | -$43.7M | -$10.9M |
| Purchase of property and equipment | -$213.3M | -$188.1M | -$176.6M |
| Proceeds from sale of equipment | $1.3M | $157.0K | $83.0K |
| Equity Contributions In Joint Ventures | -$4.1M | -$1.5M | -$14.0M |
| Collection of notes receivable | $5.7M | $0 | $0 |
| Net cash used in investing activities | -$343.9M | -$233.1M | -$201.5M |
| Principal payments on notes and leases payable | -$7.0M | -$6.0M | -$2.9M |
| Payments on term loan debt | -$20.8M | -$692.4M | -$41.1M |
| Proceeds from issuance of debt, net of issuance costs | $99.0M | $863.8M | $0 |
| Sale of noncontrolling interests | $2.4M | $22.4M | $5.1M |
| Payments of contingent consideration and holdbacks | -$2.2M | -$4.3M | -$5.5M |
| Distributions paid to noncontrolling interests | -$4.6M | -$4.5M | -$6.0M |
| Proceeds from issuance of common stock | $0 | $218.4M | $245.8M |
| Proceeds from issuance of common stock upon exercise of options | $5.4M | $667.0K | $142.0K |
| Net cash provided by financing activities | $72.2M | $397.9M | $195.6M |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH | $33.0K | -$453.0K | -$292.0K |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | $27.2M | $397.4M | $214.7M |
| Cash paid during the period for interest | $72.3M | $84.6M | $64.7M |
| Equipment acquired and leasehold improvements | $91.9M | $65.6M | $67.7M |
| Deemed contribution to joint venture | $16.3M |
No quarter-by-quarter statement was filed.
Corporate structure
RadNet, Inc. sits at the top of its group. 102 entities, 8 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of RadNet, Inc.
- RTW INVESTMENTS, LP Filed SCHEDULE 13G/A on RadNet, Inc., latest Aug 14, 2026 (2 filings since Feb 17, 2026)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G on RadNet, Inc., latest May 15, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on RadNet, Inc., latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on RadNet, Inc., latest Mar 27, 2026 (7 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on RadNet, Inc., latest Oct 17, 2025 (5 filings since Jan 25, 2022)
- Sandy Nyholm Kaminsky Filed SC 13G/A on RadNet, Inc., latest Oct 24, 2024
- BECK MACK & OLIVER LLC Filed SC 13G/A on RadNet, Inc., latest Feb 14, 2024 (2 filings since Feb 8, 2023)
- RadNet, Inc. Los Angeles, California
- Advanced /Upper Chesapeake Health Center, LLC Subsidiary · Maryland, United States
- Advanced Imaging at St. Joseph Medical Center, LLC Subsidiary · Maryland, United States
- Advanced Imaging at Timonium Crossing, LLC Subsidiary · Maryland, United States
- Advanced Imaging Partners, Inc. Subsidiary · Delaware, United States
- Advanced NA, LLC Subsidiary · Delaware, United States
- Advanced PET Imaging of Maryland, L.P. Subsidiary · Maryland, United States
- Advanced Radiology at Aberdeen, LLC Subsidiary · Maryland, United States
- Advanced Radiology, LLC Subsidiary · Maryland, United States
- Aidence B.V. Subsidiary · Netherlands
- Aidence UK Ltd. Subsidiary · United Kingdom
- American Radiology Services LLC Subsidiary · Delaware, United States
- American Radiology Services of Delaware, Inc. Subsidiary · Delaware, United States
- Aquila Medical Innovation, Inc. Subsidiary · Delaware, United States
- Arizona Diagnostic Radiology Group, LLC Subsidiary · Delaware, United States
- Arizona Imaging Services, LLC Subsidiary · Delaware, United States
- Baltimore County Radiology, LLC Subsidiary · Maryland, United States
- Baltimore Washington Imaging Center, LLC Subsidiary · Maryland, United States
- Beach Imaging Group, LLC Subsidiary · California, United States
- Calvert Medical Imaging Centers, LLC Subsidiary · Maryland, United States
- Capital Imaging at Capital Region, LLC Subsidiary · Maryland, United States
- Carroll County Radiology, LLC Subsidiary · Maryland, United States
- CIMAR CLOUD (EU) LIMITED (IRELAND) Subsidiary · Ireland
- CIMAR UK LIMITED (UK) Subsidiary · United Kingdom
- Community Imaging Partners, Inc. Subsidiary · Delaware, United States
- DeepHealth, Inc. Subsidiary · Delaware, United States
- and 76 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What RadNet, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $807.7M5 Dec 31, 2025 | $694.8M5 Dec 31, 2024 | +16.3% |
| Finance-lease assets | $401.0K5 Dec 31, 2025 | $488.0K5 Dec 31, 2024 | −17.8% |
| Operating-lease assets (leased space) | $690.2M5 Dec 31, 2025 | $639.7M5 Dec 31, 2024 | +7.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $767.2M5 Dec 31, 2025 | $740.0M5 Dec 31, 2024 | +3.7% |
| Stakes in other companies (equity method) | $10.8M5 Dec 31, 2025 | $8.0M9 Dec 31, 2024 | +35.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $907.7M5 Dec 31, 2025 | $710.7M5 Dec 31, 2024 | +27.7% |
| Intangible assets, net (excluding goodwill) | $148.5M5 Dec 31, 2025 | $81.4M9 Dec 31, 2024 | +82.6% |
| Indefinite-lived intangibles (excluding goodwill) | $18.5M5 Dec 31, 2025 | $13.0M5 Dec 31, 2024 | +42.3% |
Properties, in its own words
Our corporate headquarters is located in adjoining premises at 1508, 1510 and 1516 Cotner Avenue, Los Angeles, California 90025, and approximately 21,500 square feet is occupied under these leases, which including options, expire June 30, 2037. We also have a regional office of approximately 35,400 square feet in Baltimore, Maryland under a lease, which including options, expires September 30, 2028. In addition, we lease approximately 35,000 square feet of warehouse space nationwide, which expire at various dates, including options, through December 31, 2028.
At December 31, 2025, we operated directly or indirectly through hospital and health system joint ventures, 418 centers located in Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, New York, and Texas. We lease the premises at which these facilities are located and do not have options to purchase the facilities we rent. Our most common initial lease term varies in length from 5 to 15 years. Factoring in renewal options, we can have a total span of 10 to 35 years at the facilities we lease. We also lease smaller satellite X-Ray locations, usually for one year terms, that are renewable on mutual
The rest of Item 2
consent with the landlord. Rental increases can range from 1% to 10% on an annual basis, depending on the location and market conditions where we do business.
As of December 31, 2025, total square footage operated directly or indirectly under lease, including medical office, administrative and warehouse locations, was approximately 3.2 million square feet. All leasing activity described relates solely to our Imaging Center segment, as our Digital Health leasing activity is currently immaterial.
Item 2 of the 10-K filed Mar 2, 2026.4
Leadership
Who has led RadNet, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerStephen M. Forthuber Jun 16, 2026 to now14
- Chief executive officerCornelis Wesdorp Oct 2, 2024 to Jun 16, 202615
- Chief executive officerHoward G. Berger Jan 5, 2023 to Oct 2, 202416
- PresidentNorman R. Hames Jan 2, 2018 to Apr 5, 202117
- PresidentStephen M. Forthuber Jan 2, 2018 to Jan 10, 202018
- PresidentHoward G. Berger Feb 5, 2010 to Jan 2, 201819
- Chief financial officerStephen M. Forthuber Oct 30, 2008 to Oct 30, 200820
- Chief financial officerMark Stolper Jul 12, 2006 to Oct 30, 200821
- Chief operating officerNorman R. Hames Jan 6, 2021 to now22
- Chief operating officerStephen M. Forthuber Jan 6, 2021 to now23
Board members and other officers (26)
- EVP Chief Science OfficerAlma Gregory Sorenson Aug 18, 2023 to now24
- Chief Information OfficerRanjan Jayanathan Jan 19, 2021 to now25
- Senior Vice PresidentRuth Louisa Villigerwilson Feb 3, 2020 to Jan 6, 202226
- Executive Vice PresidentMital Patel Dec 15, 2016 to now27
- EVP, Hospital Based OperationsTodd W. Skulte Dec 3, 2014 to Jun 16, 201528
- VP Materials ManagementDerek Bomar Dec 9, 2014 to Jul 30, 201529
- Executive Vice PresidentMichael N. Murdock Jan 11, 2011 to now30
- Medical DirectorJohn Crues V. Jun 17, 2009 to Jun 14, 202131
- Executive Vice PresidentStephen M. Forthuber Apr 4, 2007 to Sep 24, 202132
- Vice PresidentJeffrey L. Linden Apr 10, 2006 to Sep 17, 201833
- Vice PresidentNorman R. Hames Apr 21, 2006 to Sep 24, 202134
- Vice chairSami S. Abbasi Nov 21, 2006 to Nov 30, 200635
- Board memberAlma Gregory Sorenson Aug 18, 2023 to now24
- Board memberChristine Nayoma Gordon Jun 14, 2021 to Jun 11, 202436
- Board memberGregory E. Spurlock Jun 14, 2021 to now37
- Board memberRuth Louisa Villigerwilson Feb 3, 2020 to Mar 6, 202326
- Board memberLaura Pastre Jacobs Jun 3, 2020 to now38
- Board memberMital Patel Jan 9, 2017 to Jan 9, 201739
- Board memberHoward G. Berger Feb 5, 2010 to now19
- Board memberMarvin S. Cadwell Mar 1, 2007 to Jun 18, 201940
- Board memberMichael L. Sherman Md. Mar 1, 2007 to Aug 21, 201941
- Board memberDavid L. Swartz Mar 29, 2006 to now42
- Board memberLawrence L. Levitt Mar 29, 2006 to now43
- Board memberNorman R. Hames Apr 21, 2006 to Apr 5, 202134
- Board memberJohn Crues V. Jul 18, 2006 to Jun 14, 202144
- Board memberSami S. Abbasi Nov 21, 2006 to Nov 21, 200635
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Advanced /Upper Chesapeake Health Center, LLC Maryland3
- Advanced Imaging Partners, Inc. Delaware3
- Advanced Imaging at St. Joseph Medical Center, LLC Maryland3
- Advanced Imaging at Timonium Crossing, LLC Maryland3
- Advanced NA, LLC Delaware3
- Advanced PET Imaging of Maryland, L.P. Maryland3
- Advanced Radiology at Aberdeen, LLC Maryland3
- Advanced Radiology, LLC Maryland3
- Aidence B.V. Netherlands3
- Aidence UK Ltd. England3
- Aidence UK, Ltd United Kingdom3
- American Radiology Services LLC Delaware3
- American Radiology Services of Delaware, Inc. Delaware3
- Aquila Medical Innovation, Inc. Delaware3
- Arizona Diagnostic Radiology Group, LLC Delaware3
- Arizona Imaging Services, LLC Delaware3
- Baltimore County Radiology, LLC Maryland3
- Baltimore Washington Imaging Center, LLC Maryland3
- Beach Imaging Group, LLC California3
- CIMAR CLOUD (EU) LIMITED (IRELAND) Ireland3
- CIMAR UK LIMITED (UK) England3
- Calvert Medical Imaging Centers, LLC Maryland3
- Capital Imaging at Capital Region, LLC Maryland3
- Carroll County Radiology, LLC Maryland3
All 107 listed subsidiaries
- Community Imaging Partners, Inc. Delaware3
- DH AI International Holdings B.V. Netherlands3
- DeepHealth, Inc. Delaware3
- Delaware Imaging Partners, Inc. Delaware3
- Diagnostic Imaging Services, Inc. Delaware3
- Diagnostic Village, LLC California3
- FRI II, Inc. California3
- FRI, Inc. California3
- Franklin Imaging, LLC Maryland3
- Frederick County Radiology, LLC Maryland3
- Garden State Radiology Network, LLC New Jersey3
- Glendale Advanced Imaging Center, LLC California3
- Greater Baltimore Diagnostic Imaging Partnership Maryland3
- Health Diagnostics of New Jersey, LLC New Jersey3
- Heart and Lung Imaging Limited United Kingdom3
- ISSI Acquisition Corp. Delaware3
- Idaho Imaging Services, Inc. Delaware3
- Ide Imaging Partners, Inc. Delaware3
- Image Medical Corporation Delaware3
- Imaging On Call, LLC New York3
- Imaging Services Company of New York, LLC New York3
- Indiana Imaging Services, Inc. Delaware3
- Integrated Health Network, Inc. New Jersey3
- Kepdoktor Kft Hungary3
- Kheiron Medical Technologies B.V. Netherlands3
- Kheiron Medical Technologies Inc. Delaware3
- Kheiron Medical Technologies KFT Hungary3
- Kheiron Medical Technologies Ltd. England and Wales3
- Mid Rockland Imaging Partners, Inc. Delaware3
- Mission Advanced Imaging Center, LLC California3
- Montgomery Community Magnetic Imaging Center Limited Partnership Maryland3
- Mount Airy Imaging Center, LLC Maryland3
- New Jersey Imaging Network, LLC New Jersey3
- New Jersey Imaging Partners, Inc. New Jersey3
- Nulogix Health, Inc. Delaware3
- Orange County Radiation Oncology, LLC California3
- Oregon Imaging Services, Inc. Delaware3
- Pacific Diagnostic Imaging Group LLC Delaware3
- Pacific Imaging Partners, Inc. California3
- PantheonXT Partners, LLC Delaware3
- Park West Circle Realty, LLC New York3
- Qualia Acquisition Corp. Delaware3
- Quantib B.V. Netherlands3
- Quantib Inc. Delaware3
- Questar Imaging, Inc. Florida3
- Questar Victorville, Inc. Florida3
- RMI Scheduling, Inc. Delaware3
- RMIS Imaging Services, Inc. Canada3
- Radar Medical Systems, LLC Michigan3
- Radiologix, Inc. Delaware3
- Radiology Alliance Delivery Systems, LLC Delaware3
- Radiology and Nuclear Medicine Imaging Partners, Inc. Delaware3
- Radnet Managed Imaging Services, Inc. California3
- Radnet Management I, Inc. California3
- Radnet Management II, Inc. California3
- Radnet Management, Inc. California3
- Radnet Sub, Inc. California3
- Radnet Tech Services Private Limited India3
- Radsite LLC Delaware3
- Raven Holdings U.S., Inc. Delaware3
- Rolling Oaks Imaging Corporation California3
- Rolling Oaks Radiology, Inc. California3
- Santa Monica Imaging Group, LLC California3
- Scriptsender, LLC Florida3
- See-Mode Technologies Pte. Ltd. Singapore3
- See-Mode Technologies Pty. Ltd. Australia3
- Simi Valley Imaging Group, LLC Delaware3
- SoCal MR Site Management, Inc. California3
- Texas Imaging Services, LLC Delaware3
- The New Jersey Imaging Partners, Inc. New Jersey3
- Treasure Coast Imaging Partners, Inc. Delaware3
- Tri Valley Imaging Group, LLC California3
- Valley Imaging Partners, Inc. California3
- Ventura County Imaging Group, LLC California3
- Virginia Imaging Services, Inc. Delaware3
- Washington Imaging Services, Inc. Delaware3
- West Valley Imaging Group, LLC California3
- Xoft Solutions, LLC Delaware3
- Xoft, Inc. Delaware3
- eRad, Inc. Pennsylvania3
- iCAD France, LLC Delaware3
- iCAD Italy, LLC Delaware3
- iCAD, Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- PRIMEDEX HEALTH SYSTEMS INCNov 1, 1996 to Nov 21, 20062
Timeline
- Aug 14, 20268-K Other events45
- Aug 10, 20268-K Results of operations46
- Jun 16, 2026New chief executive Stephen M. Forthuber becomes CEO14
- Jun 10, 20268-K Entered a material agreement; New debt or obligation; Regulation FD disclosure47
- Jun 4, 20268-K Shareholder vote48
- Jun 3, 20268-K Other events49
- May 11, 20268-K Results of operations50
- Mar 2, 20268-K Regulation FD disclosure51
- Mar 2, 20268-K Results of operations52
- Jan 30, 20268-K Other events53
- Jan 9, 20268-K Executive or director change; Regulation FD disclosure54
- Dec 4, 20258-K Other events55
- Nov 10, 20258-K Results of operations56
- Oct 2, 2024New chief executive Cornelis Wesdorp becomes CEO15
- Jan 5, 2023New chief executive Howard G. Berger becomes CEO16
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.20 a share, on Nov 9, 2025.57
When it reported results
- Aug 10, 2026Reported quarterly or annual results46
- May 11, 2026Reported quarterly or annual results50
- Mar 2, 2026Reported quarterly or annual results52
- Nov 10, 2025Reported quarterly or annual results56
- Aug 11, 2025Reported quarterly or annual results58
- May 12, 2025Reported quarterly or annual results59
- Mar 5, 2025Reported quarterly or annual results60
- Nov 12, 2024Reported quarterly or annual results61
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
372 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 51 major events, 175 insider forms, 19 large holders, 106 other. The latest 20:
- Aug 14, 20268-K CURRENT REPORT EDGAR
- Aug 14, 2026424B7 PROSPECTUS EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 20268-K EDGAR
- Aug 10, 202610-Q EDGAR
- Jun 22, 20264 EDGAR
- Jun 18, 2026144 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 16, 2026144 EDGAR
- Jun 16, 20264 EDGAR
- Jun 15, 2026144 EDGAR
- Jun 10, 20268-K EDGAR
- Jun 4, 20268-K CURRENT REPORT EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20268-K CURRENT REPORT EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
The 372 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
73 open-market trades by officers, directors and large owners since October 2021: 0 buys and 73 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | SWARTZ DAVID LDirector | Sale | 2,699 | $53.89 | $145.4K | Form 4 |
| Jun 16, 2026 | Wesdorp CornelisPres & CEO, Digital Health | Sale | 4,750 | $58.11 | $276.0K | Form 4 |
| Jun 15, 2026 | Forthuber Stephen MPres & CEO-Eastern Operations | Sale | 44,067 | $58.16 | $2.6M | Form 4 |
| Mar 19, 2026 | Sorensen Alma GregoryChief Strategy Officer | Sale | 15,000 | $62.20 | $933.0K | Form 4 |
| Mar 18, 2026 | Sorensen Alma GregoryChief Strategy Officer | Sale | 15,000 | $62.15 | $932.3K | Form 4 |
| Dec 5, 2025 | Forthuber Stephen MPres & CEO-Eastern Operations | Sale | 45,088 | $78.33 | $3.5M | Form 4 |
| Nov 19, 2025 | Patel MitalEVP of Fin Planning, CAO | Sale | 15,080 | $80.05 | $1.2M | Form 4 |
| Nov 18, 2025 | Patel MitalEVP of Fin Planning, CAO | Sale | 9,920 | $80.00 | $793.6K | Form 4 |
| Nov 17, 2025 | Patel MitalEVP of Fin Planning, CAO | Sale | 25,000 | $76.06 | $1.9M | Form 4 |
| Sep 16, 2025 | STOLPER MARKEVP, Chief Financial Officer | Sale | 35,000 | $73.89 | $2.6M | Form 4 |
| Sep 16, 2025 | Katz David JeffreyEVP and Chief Legal Officer | Sale | 14,000 | $74.44 | $1.0M | Form 4 |
| Sep 11, 2025 | Wesdorp CornelisPres & CEO, Digital Health | Sale | 500 | $72.13 | $36.1K | Form 4 |
| Sep 10, 2025 | HAMES NORMAN RPres and COO-West Operations | Sale | 10,000 | $72.74 | $727.4K | Form 4 |
| Sep 9, 2025 | Wesdorp CornelisPres & CEO, Digital Health | Sale | 500 | $71.99 | $36.0K | Form 4 |
| Aug 27, 2025 | HAMES NORMAN RPres and COO-West Operations | Sale | 5,000 | $71.10 | $355.5K | Form 4 |
| Aug 19, 2025 | Wesdorp CornelisPres & CEO, Digital Health | Sale | 1,500 | $66.98 | $100.5K | Form 4 |
| Aug 19, 2025 | Jayanathan RanjanChief Information Officer | Sale | 65,598 | $67.50 | $4.4M | Form 4 |
| Aug 13, 2025 | Katz David JeffreyEVP and Chief Legal Officer | Sale | 17,000 | $68.31 | $1.2M | Form 4 |
| Jun 5, 2025 | Murdock Michael NEVP, Mergers and Acquisitions | Sale | 11,132 | $58.05 | $646.2K | Form 4 |
| May 23, 2025 | Sorensen Alma GregoryChief Strategy Officer | Sale | 55,000 | $56.48 | $3.1M | Form 4 |
All 73 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- RTW INVESTMENTS, LPSCHEDULE 13G/A, 2 filings Feb 17, 2026 to Aug 14, 202662
- PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G, 1 filing May 15, 202663
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202664
- VANGUARD GROUP INCSCHEDULE 13G/A, 7 filings Feb 10, 2022 to Mar 27, 202665
- BlackRockSCHEDULE 13G/A, 5 filings Jan 25, 2022 to Oct 17, 202566
- Sandy Nyholm KaminskySC 13G/A, 1 filing Oct 24, 202467
- BECK MACK & OLIVER LLCSC 13G/A, 2 filings Feb 8, 2023 to Feb 14, 202468
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Howard G. BergerM.D. | 81 | $3.0M | $12.1M69 |
| 2025 | Stephen M. Forthuber | 65 | $800.0K | $3.3M69 |
| 2025 | Norman R. Hames | 70 | $800.0K | $3.2M69 |
| 2025 | Mital Patel | 40 | $750.0K | $3.1M69 |
| 2025 | Mark D. Stolper | 54 | $700.0K | $2.8M69 |
| 2024 | President and Chief Executive Officer | $3.0M | $9.1M69 | |
| 2024 | President and Chief Operating | $800.0K | $2.2M69 | |
| 2024 | Executive VicePresident and | $700.0K | $1.9M69 | |
| 2023 | (principal executive officer) | $1.5M | $6.7M69 | |
| 2023 | Officer - Eastern Operations | $650.0K | $2.2M69 | |
| 2023 | Officer - Western Operations | $650.0K | $2.1M69 | |
| 2023 | Planning and Analysis and Chief Administrative Officer | $575.0K | $1.9M69 | |
| 2023 | Chief Financial Officer(principal financial officer) | $575.0K | $1.9M69 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 10,957,808 | $675.8M | 0.0% | +922,074 |
| Rtw Investments, LP | 4,846,958 | $298.9M | 2.6% | +561,958 |
| Vanguard Portfolio Management LLC | 4,066,931 | $250.8M | 0.0% | +167,804 |
| Vanguard Capital Management LLC | 3,193,565 | $196.9M | 0.0% | +82,553 |
| Beck Mack & Oliver LLC | 3,163,592 | $195.1M | 3.8% | −2,600 |
| State Street Corp | 2,842,457 | $175.2M | 0.0% | +190,859 |
| Geode Capital Management, LLC | 1,858,508 | $114.6M | 0.0% | +134,901 |
| Invesco Ltd. | 1,641,292 | $101.2M | 0.0% | +7,797 |
| American Century Companies Inc | 1,618,424 | $99.8M | 0.0% | +716,232 |
| Clearbridge Investments, LLC | 1,546,652 | $95.4M | 0.1% | +268,112 |
| Dimensional Fund Advisors LP | 1,491,040 | $91.9M | 0.0% | +112,037 |
| Hood River Capital Management LLC | 1,456,205 | $89.8M | 0.7% | +44,708 |
| Jb Capital Partners LP | 1,424,061 | $87.8M | 13.6% | No change |
| Bamco Inc /ny/ | 1,260,992 | $77.8M | 0.1% | +450,926 |
| Defiance ETFs, LLC | 1,143,622 | $75.0M | 1.0% | +598,148 |
| Goldman Sachs Group Inc | 1,178,372 | $72.7M | 0.0% | −11,903 |
| Alyeska Investment Group, L.P. | 1,171,721 | $72.3M | 0.2% | −137,587 |
| Principal Financial Group Inc | 1,052,356 | $64.9M | 0.0% | −58,921 |
| Westfield Capital Management Co LP | 975,542 | $60.2M | 0.2% | +443,649 |
| Morgan Stanley | 931,114 | $57.4M | 0.0% | +80,643 |
| Northern Trust Corp | 813,056 | $50.1M | 0.0% | +66,249 |
| Charles Schwab Investment Management Inc | 792,282 | $48.9M | 0.0% | +24,811 |
| Rockefeller Capital Management L.P. | 757,990 | $46.7M | 0.1% | +54,874 |
| Ameriprise Financial Inc | 745,603 | $46.0M | 0.0% | −153,523 |
| Global Alpha Capital Management Ltd. | 734,875 | $45.3M | 2.7% | +76,667 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How RadNet, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRadNet, Inc.1
- CIK0000790526
- Employer ID (EIN)13-33267244
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)8071 Services-Medical Laboratories1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address1510 Cotner Ave, Los Angeles, CA 900251
- Phone31047878081
- Shares outstanding78,697,257 as of Aug 6, 202611
- Public float$4.1B as of Jun 30, 20254
- AuditorErnst & Young LLP, Los Angeles, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceMar 21, 19961
- Filings1,364 in all: 4 (610), 8-K (224), 10-Q (93), 144 (43), SC 13G/A (38), 4/A (36), 10-K (31), 425 (28)1
All 52 form types
3 (23), DEF 14A (21), UPLOAD (18), 8-K/A (15), CORRESP (15), SC 13G (15), 10-K/A (14), NT 10-Q (14), SC 13D/A (13), S-8 (12), NT 10-K (10), DEFA14A (9), 10-Q/A (8), 424B7 (7), EFFECT (5), 3/A (4), 424B5 (4), 5 (4), ARS (4), S-4/A (4), SC 13D (4), SCHEDULE 13G/A (4), 424B3 (3), PRE 14A (3), S-3ASR (3), S-4 (3), S-8 POS (3), SCHEDULE 13G (3), 10-KT (1), 5/A (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), CT ORDER (1), DEFM14A (1), DEFR14A (1), NT 10-Q/A (1), NTN 10K (1), POS AM (1), PRER14A (1), PX14A6G (1), RW (1), S-3 (1), T-3 (1)
- Latest filingsAnnual report (10-K) Mar 2, 2026
Quarterly report (10-Q) Aug 10, 2026
Proxy statement (DEF 14A) Apr 20, 2026
Latest 8-K (8-K) Aug 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $.0001 par value | RDNT | NASDAQ Global Market |
From the cover page of the 10-K filed Mar 2, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks RadNet, Inc. names in Item 1A of its 10-K filed Mar 2, 2026: 44 risks under these headings, as written.4
- General Economic and Industry Risks
- Adverse changes in general domestic and worldwide economic conditions could adversely affect our operating results, financial condition, and liquidity.
- A worsening of the economic and employment conditions in the geographies in which we operate could materially affect our business and future results of operations.
- Increases in inflation and rising interest rates or disruption of credit markets could adversely affect our financial condition and liquidity.
- Our labor costs have been, and we expect will continue to be, adversely affected by competition for staffing, the shortage of experienced healthcare professionals, and regulatory activity including changes in minimum wage laws.
- We face various risks related to health epidemics and other outbreaks, which may have a material adverse effect on our business, financial condition, results of operations and cash flows.
- Business interruptions due to natural disasters to include but not limited to earthquakes, floods, fires, hurricanes and severe winter storms or other external events beyond our control can adversely affect our business, financial condition or results of operations.
- Changes in the method or rates of third-party reimbursement could have a negative impact on our results.
- If we fail to manage the complex and lengthy reimbursement process, our revenue, financial condition and results of operations could suffer.
- We experience competition from other diagnostic imaging companies and hospitals, and this competition could adversely affect our revenue and business.
- Technological change in our industry could reduce the demand for our services and require us to incur significant costs to upgrade our equipment.
- Business Risks
The other 34 risks
- Our results of operations may fluctuate significantly from period to period and can be difficult to predict.
- If our contracted radiology practices terminate their agreements with us, our business could substantially diminish.
- We are dependent on the ability of our contracted radiology practices, including the Group, to hire and retain qualified radiologists.
- Our ability to generate revenue depends in large part on referrals from physicians.
- We may become subject to professional malpractice liability, which could be costly and negatively impact our reputation and business.
- We may not receive payment from some of our healthcare provider customers because of their financial circumstances.
- Capitation fee arrangements could reduce our operating margins.
- Cybersecurity threats and other disruption or malfunction in our information technology systems could adversely affect our business.
- Our success depends in part on our key personnel and loss of key executives could adversely affect our operations.
- The future growth of our imaging business is partially dependent on our ability to continue to successfully integrate acquired businesses.
- We may not generate the expected benefits from our investment in AI technologies or other new lines of business and the use of AI and machine learning tools in our operations and the services of our third-parties may introduce risks that could adversely affect our business, financial condition, and reputation.
- Healthcare and Regulatory Risks
- The regulatory framework in which we operate is continually evolving.
- If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting U.S. healthcare reform, our business could be harmed.
- We may be impacted by eligibility changes to government and private insurance programs.
- Complying with federal and state regulations is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
- There may be changes in FDA’s regulatory requirements and policies, and we may not be able to comply with them.
- State and federal anti-kickback and anti-self-referral laws may adversely affect income.
- If we fail to comply with various licensure, certification and accreditation standards, we may be subject to loss of licensure, certification or accreditation, which would adversely affect our operations.
- Our agreements with the contracted radiology practices must be structured to avoid the corporate practice of medicine and fee-splitting.
- Our software products could be regulated as medical devices by regulatory agencies, and we may be subject to such agencies’ regulatory or enforcement activities.
- If we fail to comply with federal and state privacy and information security laws mandating protection of certain confidential data against disclosure, including cybersecurity attacks, we may be subject to government or private actions.
- Some of our imaging modalities use radioactive materials, which generate regulated waste and could subject us to liabilities for injuries or violations of environmental and health and safety laws.
- If CMS ends its current policy permitting professionals to provide direct supervision of diagnostic imaging to be immediately available through virtual presence using two-way, real-time audio/video technology, instead of requiring their physical presence, we may be subject to additional costs and a shortage of professionals to provide such supervision.
- Financial Risks
- Because we have high fixed costs, lower scan volumes or other decreases revenues could adversely affect the profitability of our business.
- Our debt could adversely affect our financial condition and prevent us from fulfilling our obligations under our outstanding indebtedness.
- A restriction in our ability to make capital expenditures would restrict our growth and could adversely affect our business.
- We may be required to recognize an impairment of our goodwill, other intangible assets, or other long-lived assets, which could have an adverse effect on our financial position and results of operations.
- Our credit facilities and instruments governing our other indebtedness restrict certain operations of our business.
- If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.
- Capital Markets Risks
- Possible volatility in our stock price could negatively affect us and our stockholders.
- Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could cause the price of our common stock to fall.
- Future issuances of our common stock or rights to purchase our common stock could result in additional dilution to the percentage ownership of our stockholders and could cause the price of our common stock to fall.
- We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our common stock.
- Provisions of the Delaware General Corporation Law and our organizational documents may discourage an acquisition of us.
Legal proceedings
From time to time we are engaged in the defense of lawsuits arising out of the ordinary course of our business. We do not believe that the outcome of our current litigation will have a material adverse impact on our business, financial condition and results of operations. However, the outcome of litigation is inherently uncertain. If one or more legal matters were resolved against us in a reporting period for amounts above management’s expectations, our financial condition and operating results could be materially adversely affected.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARRadNet, Inc. filings on SEC EDGAR
- 2SEC EDGARRadNet, Inc. filings on SEC EDGAR
- 3
- 4
- 5SEC EDGARRadNet, Inc. 10-K for fiscal 2025
- 6SEC EDGARRadNet, Inc. 10-K for fiscal 2019
- 7SEC EDGARRadNet, Inc. 10-K for fiscal 2020
- 8SEC EDGARRadNet, Inc. 10-K for fiscal 2021
- 9SEC EDGARRadNet, Inc. 10-K for fiscal 2022
- 10SEC EDGARRadNet, Inc. 10-Q for fiscal 2026
- 11SEC EDGARRadNet, Inc. 10-Q for fiscal 2026
- 12SEC EDGARRadNet, Inc. 10-K for fiscal 2019
- 13SEC EDGARRadNet, Inc. 10-K for fiscal 2019
- 14
- 15
- 16
- 17SEC EDGARNorman R. Hames, President
- 18SEC EDGARStephen M. Forthuber, President
- 19SEC EDGARHoward G. Berger, President
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARDerek Bomar, VP Materials Management
- 30
- 31SEC EDGARJohn Crues V., Medical Director
- 32
- 33SEC EDGARJeffrey L. Linden, Vice President
- 34SEC EDGARNorman R. Hames, Vice President
- 35SEC EDGARSami S. Abbasi, Vice chair
- 36
- 37SEC EDGARGregory E. Spurlock, Board member
- 38SEC EDGARLaura Pastre Jacobs, Board member
- 39SEC EDGARMital Patel, Board member
- 40SEC EDGARMarvin S. Cadwell, Board member
- 41SEC EDGARMichael L. Sherman Md., Board member
- 42SEC EDGARDavid L. Swartz, Board member
- 43SEC EDGARLawrence L. Levitt, Board member
- 44SEC EDGARJohn Crues V., Board member
- 45SEC EDGAROther events
- 46SEC EDGARResults of operations
- 47
- 48SEC EDGARShareholder vote
- 49SEC EDGAROther events
- 50SEC EDGARResults of operations
- 51SEC EDGARRegulation FD disclosure
- 52SEC EDGARResults of operations
- 53SEC EDGAROther events
- 54
- 55SEC EDGAROther events
- 56SEC EDGARResults of operations
- 57NasdaqNasdaq calendar
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69